A joint study by the NHS, Imperial College London and Google Health evaluated almost 116,000 women. The algorithm replaced one of two mammogram readers, raising the cancer detection rate from 7.54 to 9.33 per thousand patients. That is an increase of 1.79 cases, or roughly 25 percent more interval tumors that often escape first‑time screening.
False‑positive recalls fell by 39.3 percent. Fewer referrals mean less workload for radiologists and a clear cost saving. At an average cost of 30,000 rubles per additional test, clinics could save about 1.4 million rubles across the entire screening cohort.
The AI assistant reshapes double reading. Instead of two independent physicians, a hybrid "human + AI" model emerges, with radiologists reviewing only contentious cases. Throughput rises by roughly 12 percent, allowing more patients to be served without hiring new staff.
For a typical network of five centers handling about 600,000 screenings annually, savings from reduced false positives and lower late‑treatment expenses could exceed 7 million rubles. Licensing and integration costs pay for themselves within 12 to 14 months if current volumes remain steady.
What does this mean for your business now? Hybrid reading cuts operating costs and lifts productivity, but it forces a rethink of liability protocols. You must assess legal risk, build an ROI model and embed the AI assistant into your double‑reading workflow. Otherwise competitors will already be leveraging AI while you are still debating regulatory details.
Why this matters: Adopt the hybrid model now to lock in cost savings and capacity gains before rivals do. Align governance with the new workflow to avoid legal exposure. Track performance metrics closely to validate ROI within the first year.